BR112015012422A2 - formulação liofilizada de tat-nr2b9c - Google Patents
formulação liofilizada de tat-nr2b9cInfo
- Publication number
- BR112015012422A2 BR112015012422A2 BR112015012422A BR112015012422A BR112015012422A2 BR 112015012422 A2 BR112015012422 A2 BR 112015012422A2 BR 112015012422 A BR112015012422 A BR 112015012422A BR 112015012422 A BR112015012422 A BR 112015012422A BR 112015012422 A2 BR112015012422 A2 BR 112015012422A2
- Authority
- BR
- Brazil
- Prior art keywords
- tat
- nr2b9c
- formulation
- lyophilized
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
resumo da patente de invenã§ã£o para: âformulaãão liofilizada de tat-nr2b9câ. a invenã§ã£o refere-se a formulaã§ãµes liofilizadas de agentes ativos, particularmente de tat-nr2b9c. tat-nr2b9c tem se mostrado promissora para o tratamento de acidente vascular cerebral, aneurisma, hemorragia subaracnã³idea e outras condiã§ãµes neurolã³gicas ou neuro-traumã¡ticas. tais formulaã§ãµes sã£o estã¡veis ã temperatura ambiente facilitando assim a manutenã§ã£o das entregas de tal formulaã§ã£o em ambulã¢ncias para administraã§ã£o no local de acidente ou doenã§a, ou em trã¢nsito para um hospital.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261730952P | 2012-11-28 | 2012-11-28 | |
| US61/730,952 | 2012-11-28 | ||
| PCT/US2013/071755 WO2014085349A1 (en) | 2012-11-28 | 2013-11-25 | Lyophilized formulation of tat-nr2b9c |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015012422A2 true BR112015012422A2 (pt) | 2017-09-12 |
| BR112015012422B1 BR112015012422B1 (pt) | 2023-07-04 |
Family
ID=
Also Published As
| Publication number | Publication date |
|---|---|
| KR102166374B1 (ko) | 2020-10-15 |
| WO2014085349A1 (en) | 2014-06-05 |
| TR201905787T4 (tr) | 2019-05-21 |
| HK1215793A1 (zh) | 2016-09-15 |
| US20140162957A1 (en) | 2014-06-12 |
| MX2015006784A (es) | 2015-10-29 |
| EP2925338A1 (en) | 2015-10-07 |
| CN105101986B (zh) | 2018-09-25 |
| CA2892965C (en) | 2021-06-01 |
| JP6427104B2 (ja) | 2018-11-21 |
| EP2925338A4 (en) | 2016-05-25 |
| AU2013352437A1 (en) | 2015-07-09 |
| JP2016502537A (ja) | 2016-01-28 |
| CN105101986A (zh) | 2015-11-25 |
| SI2925338T1 (sl) | 2019-09-30 |
| DK2925338T3 (da) | 2019-05-06 |
| HUE043820T2 (hu) | 2019-09-30 |
| KR20150094656A (ko) | 2015-08-19 |
| EP2925338B1 (en) | 2019-03-27 |
| MX365325B (es) | 2019-05-29 |
| LT2925338T (lt) | 2019-05-10 |
| EP2925338B8 (en) | 2019-05-22 |
| CA2892965A1 (en) | 2014-06-05 |
| PT2925338T (pt) | 2019-05-31 |
| CN109106941A (zh) | 2019-01-01 |
| PL2925338T3 (pl) | 2019-11-29 |
| AU2013352437B2 (en) | 2018-04-12 |
| HRP20190707T1 (hr) | 2019-10-04 |
| ES2725598T3 (es) | 2019-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2892965C (en) | Lyophilized formulation of tat-nr2b9c | |
| MX2020009633A (es) | Sal de cloruro de tat-nr2b9c. | |
| BR112015004530A2 (pt) | sistema de impressão tridimensional e montagem de equipamento | |
| WO2012142511A3 (en) | Orthomolecular compositions and their use in stabilizing the extracellular matrix | |
| BR112014014147A8 (pt) | líquidos finos coesivos para a promoção da deglutição segura em pacientes disfágicos | |
| UA111588C2 (uk) | Композиція інгібітора jak для місцевого застосування | |
| WO2012103038A3 (en) | Nanoparticle compositions, formulations thereof, and uses therefor | |
| BR112013022788A2 (pt) | "composição farmacêutica compreendendo uma dispersão sólida de 1-(4-benzidrilpiperazin-1-il)-3,3-difenilpropan-1-ona" | |
| MX2015003728A (es) | Combinacion de regorafenib y acido acetilsalicilico para el tratamiento del cancer. | |
| JO3122B1 (ar) | مشتقات إسترا-5،3،1(10)، 16- تترايين-3- كربوكساميد، عمليات لتحضيرها، مستحضرات دوائية تشتمل عليها واستخدامها لتحضير أدوية | |
| PH12014501937A1 (en) | Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative | |
| MX361349B (es) | Moduladores del receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dérmicas. | |
| BR112014027965A2 (pt) | composições de polimorfos, métodos de produção, e usos das mesmas | |
| NI201300045A (es) | Inhibidores de apoptosis y usos de los mismos. | |
| WO2013138628A3 (en) | Injectable ibuprofen formulation | |
| BR112015005942A2 (pt) | extratos de cynara scolymus, coffea spp. e olea europaea para tratamento de síndrome metabólica | |
| BR112015007360A2 (pt) | composição farmacêutica, e, método para a preparação de uma droga de combinação | |
| SI2961481T1 (en) | Topical antimicrobial dermatological composition | |
| MX2016005415A (es) | Composiciones de fosfato de calcio sustituido con magnesio amorfo, y sus usos. | |
| BR112015014137A2 (pt) | unidade sólida com alto teor de fexofenadina e processo para a preparação da mesma | |
| BR112014027213A8 (pt) | nova composição de alfentanil para o tratamento de dor aguda | |
| BR112014030288A2 (pt) | composição farmacêutica | |
| WO2014178007A3 (en) | A pharmaceutical composition comprising a combination of probiotic and prebiotic | |
| ITMI20080114A1 (it) | Formulazioni topiche in forma di gel acquosi per il trattamento di dermatite atopica o come veicoli per la somministrazione transdermica di farmaci | |
| Jayasuriya | Reminiscences of Ittapana, 1963-65 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: NONO INC. (CA) |
|
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/11/2013, OBSERVADAS AS CONDICOES LEGAIS |